Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22201170 | 0.86 | ADORA2A (0.46) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| Bromide SCHEMBL7166632 | 0.85 | ADORA2A (0.44) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL12775201 | 0.84 | HSD17B10 (0.37) | ADORA2APIK3CGNOS1DHFR | |
| SCHEMBL23028961 | 0.83 | HSD17B10 (0.49) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL7761455 | 0.83 | HSD17B10 (0.49) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL25899100 | 0.83 | HSD17B10 (0.39) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL11471050 | 0.82 | ADORA2A (0.48) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL23028978 | 0.79 | NOS1 (0.45) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL23028942 | 0.79 | NOS1 (0.45) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL3692533 | 0.79 | ADORA2A (0.57) | ADORA2APIK3CGNOS1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | ADORA2A 637/4885PIK3CG 1942/4885NOS1 4318/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | ADORA2A 465/4885PIK3CG 1698/4885NOS1 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.